The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
Development of three-dimensional cancer cell line spheroid models for the in vitro functional
characterization of cytotoxic antibody-drug conjugates
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
ZW171, a T Cell-Engaging, Bispecific Antibody for the Treatment of Mesothelin-Expressing Solid Tumors
